Related Experiment Video
Updated: Aug 14, 2026
07:24
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
1University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
Journal of Cardiac Failure
|January 30, 2003
Summary
Aldosterone receptor antagonists improve ventricular remodeling in heart failure patients, unlike loop diuretics. This effect may reduce heart failure deaths by impacting myocardial collagen and hypertrophy.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Loop diuretics do not improve ventricular remodeling in heart failure.
- Aldosterone receptor antagonists show promise in improving ventricular remodeling.
Purpose of the Study:
- To investigate the effects of aldosterone receptor antagonists on ventricular remodeling in heart failure.
- To explore the mechanisms behind the beneficial effects of aldosterone receptor antagonists.
Main Methods:
- Review of existing evidence on loop diuretics and aldosterone receptor antagonists.
- Analysis of data from the Randomized Aldosterone Evaluation Study (RALES).
- Anticipation of results from the Eplerenone Heart Failure Efficacy and Survival Study (EPHESUS).
Main Results:
- No evidence supports loop diuretics improving ventricular remodeling.
- Aldosterone receptor antagonists improve ventricular remodeling in left ventricular systolic dysfunction.
- The Randomized Aldosterone Evaluation Study (RALES) indicated a reduction in heart failure deaths.
Conclusions:
- Aldosterone receptor antagonists are beneficial for ventricular remodeling and reducing mortality in heart failure.
- Mechanisms likely involve effects on myocardial collagen formation and ventricular hypertrophy.
- Further studies like EPHESUS are evaluating specific agents like eplerenone.
More Related Videos
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...